0000950170-24-019416.txt : 20240223 0000950170-24-019416.hdr.sgml : 20240223 20240223163014 ACCESSION NUMBER: 0000950170-24-019416 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240222 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240223 DATE AS OF CHANGE: 20240223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001604464 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460920988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36548 FILM NUMBER: 24671685 BUSINESS ADDRESS: STREET 1: 2380 CONEJO SPECTRUM ST STREET 2: SUITE 200 CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: 805-623-4244 MAIL ADDRESS: STREET 1: 2380 CONEJO SPECTRUM ST STREET 2: SUITE 200 CITY: THOUSAND OAKS STATE: CA ZIP: 91320 8-K 1 atra-20240222.htm 8-K 8-K
0001604464false00016044642024-02-222024-02-22

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 22, 2024

 

 

Atara Biotherapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36548

46-0920988

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2380 Conejo Spectrum Street

Suite 200

 

Thousand Oaks, California

 

91320

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (805) 623-4211

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

ATRA

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 8, 2024, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), announced that in connection with the Company’s reduction in force, the employment of the Company’s Executive Vice President, Chief Medical Officer would terminate effective as of February 2, 2024 and that in connection with such termination, Dr. Joshi would enter into a consulting agreement with the Company pursuant to which Dr. Joshi will provide consulting services to the Company through January 31, 2025. Dr. Joshi’s last day of employment with the Company is February 2, 2024.

 

On February 22, 2024, Dr. Joshi and the Company entered into a consulting agreement pursuant to which he will receive a consulting fee of $3,000 monthly for up to a specified number of consulting hours per month and will receive additional compensation of $300 per hour in excess of such specified number of consulting hours. Dr. Joshi’s outstanding restricted stock unit equity awards will continue to vest during the consulting term. In addition, subject to the terms of the consulting agreement, Dr. Joshi will be entitled to receive $180,000 upon the approval by the United States Food and Drug Administration of a biologics license application for tabelecleucel.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ATARA BIOTHERAPEUTICS, INC.

 

 

 

 

Date:

February 23, 2024

By:

/s/ Amar Murugan

 

 

 

Amar Murugan
Chief Legal Officer

 

 EX-101.SCH 2 atra-20240222.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 3 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document And Entity Information
Feb. 22, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 22, 2024
Entity Registrant Name Atara Biotherapeutics, Inc.
Entity Central Index Key 0001604464
Entity Emerging Growth Company false
Entity File Number 001-36548
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-0920988
Entity Address, Address Line One 2380 Conejo Spectrum Street
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Thousand Oaks
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91320
City Area Code (805)
Local Phone Number 623-4211
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ATRA
Security Exchange Name NASDAQ
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports atra-20240222.htm atra-20240222.xsd http://xbrl.sec.gov/dei/2023 false false JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "atra-20240222.htm": { "nsprefix": "atra", "nsuri": "http://www.atarabio.com/20240222", "dts": { "inline": { "local": [ "atra-20240222.htm" ] }, "schema": { "local": [ "atra-20240222.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_d1e2f1c7-f569-419e-9957-295925f8d813", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "atra-20240222.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d1e2f1c7-f569-419e-9957-295925f8d813", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "atra-20240222.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.atarabio.com/20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 12 0000950170-24-019416-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-019416-xbrl.zip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atra-20240222_htm.xml IDEA: XBRL DOCUMENT 0001604464 2024-02-22 2024-02-22 0001604464 false 8-K 2024-02-22 Atara Biotherapeutics, Inc. DE 001-36548 46-0920988 2380 Conejo Spectrum Street Suite 200 Thousand Oaks CA 91320 (805) 623-4211 false false false false Common Stock, par value $0.0001 per share ATRA NASDAQ false